NARA Discovery
Article Details
← Back to Search Results
Journal Article

Nitrofurantoin for the treatment of uncomplicated urinary tract infection in female patients: the impact of dosing regimen, age, and renal function on drug exposure

A. A. van Driel; A. E. Muller; R. A. Wijma; E. E. Stobberingh; A. Verbon; B. C. P. Koch
European Journal of Clinical Pharmacology · Vol. 79, Issue 8 · pp. 1043-1049 · 2023

Abstract

Purpose The aim of this study is to determine nitrofurantoin exposure in female patients with different age and renal function with complaints of an uncomplicated UTI. Also the nitrofurantoin exposure in relation to the dosage regimen will be studied. Methods Eight general practitioners (GP) participated in the study and included 38 patients with symptoms of an uncomplicated UTI, treated either with a dose of 50 mg q6h or 100 mg q12h, upon the discretion of the GP. Nitrofurantoin exposure was quantified in the patient’s 24-h urine samples by UHPLC-UV and the area under the curve was calculated. Results The 38 patients provided a range of 2–17 urine samples. The urine nitrofurantoin exposure was 1028 mg h/L for the patients receiving 50 mg q6h and 1036 mg h/L for those treated with 100 mg q12h ( p = 0.97) and was not affected by age and eGFR ( p = 0.64 and p = 0.34, respectively). Conclusion The data obtained do not support the discouragement of nitrofurantoin use in the elderly and in patients with impaired renal function. Since only a small number of patients were included, a larger study with more patients is warranted to evaluate nitrofurantoin exposure and adverse effects.

Bibliographic Information

JournalEuropean Journal of Clinical Pharmacology
PublisherSpringer
Publication Date2023-08-01
Publication Year2023
Volume79
Issue8
Pages1043-1049
Document TypeJournal Article
Print ISSN0031-6970
eISSN1432-1041
DOI10.1007/s00228-023-03507-2

Access Information

NARA Access Coverage1968-01-01~Current
Journal Homepagehttps://www.springer.com/journal/228
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.